StockData
Damora Therapeutics, Inc. logo

Damora Therapeutics, Inc. (DMRA) stock

DMRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$22.56+0.06 (+0.29%)

Close on Nov 17, 2026Market cap $1.39BP/E 5.7Yield 0.00%

Earnings

Damora Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Damora Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2025ended Dec 31, 2025Mar 10, 2026before the open–––Release
Q4 FY2022ended Dec 31, 2022Jan 6, 2023before the open–––Release
Q4 FY2020ended Dec 31, 2020Jan 5, 2021during market hours–––Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Damora Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Damora Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Damora Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. Update
  3. Results
  4. Update
  5. Update
  6. Update
  7. Update
  8. Update
  9. Update
  10. News
  11. News
  12. Update
  13. Results
  14. Update
  15. Update

See a number that looks wrong?